Market News & Trends
Etherna Announces Discovery of Novel mRNA Immunotherapeutic Delivered Via Lipid Nanoparticles That Has Demonstrated Ability to Eradicate Tumors in Preclinical Models
etherna, a biotech company pioneering mRNA and lipid-based-nanoparticle (LNP) technologies, recently announced the publication of pre-clinical data showing the therapeutic potential of a new mixture…
Monte Rosa Therapeutics Announces Closing of Global License Agreement With Novartis
Monte Rosa Therapeutics, Inc. recently announced the closing of its previously announced global exclusive development and commercialization license agreement with Novartis to advance VAV1-directed MGDs,…
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial
Candel Therapeutics, Inc. recently announced results from a multicenter phase 3 clinical trial evaluating CAN-2409 viral immunotherapy in localized prostate cancer patients. In the US alone,…
EORTC & Immunocore Announce Enrolment of First Patient Onto the Only Active Phase 3 Adjuvant Trial in Uveal Melanoma
The European Organisation for Research and Treatment of Cancer (EORTC) and Immunocore Holdings plc recently announced the randomization of the first patient in the Phase…
ProQR Therapeutics Announces $8.1 Million in New Funding From Rett Syndrome Research Trust to Expand RNA Editing Collaboration
ProQR Therapeutics NV recently announced an expansion of its collaboration with the Rett Syndrome Research Trust (RSRT). Building on the initial $1 million research grant…
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-Escalation Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Patients With Relapsed/Refractory Lymphoid Malignancies
Prelude Therapeutics Incorporated recently announced the presentation of the first interim clinical data from its ongoing open-label, dose-escalation trial of PRT2527, a potent and highly…
BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer
BriaCell Therapeutics Corp. will showcased its impressive survival and clinical benefit data in MBC patients, including those with CNS metastases, treated with the Bria-IMT plus…
Hepion Pharmaceuticals Announces Termination of Merger Agreement
Hepion Pharmaceuticals, Inc. recently announced it has entered into a termination agreement with Pharma Two B Ltd. which terminates the merger agreement between the two…
Enlivex Receives Regulatory Authorization for the Initiation of a Phase 1 Trial Evaluating Allocetra in Patients With TMJ Osteoarthritis
Enlivex Therapeutics Ltd. recently announced the Israeli Ministry of Health authorized the initiation of an investigator-initiated Phase 1 trial to evaluate the safety, tolerability, and…
Arvinas & Pfizer Announce Initial Phase 1b Data From the TACTIVE-U Sub-Study of Vepdegestrant in Combination With Abemaciclib
Arvinas, Inc. and Pfizer Inc. recently announced preliminary data from the ongoing Phase 1b portion of the TACTIVE-U sub-study of vepdegestrant in combination with abemaciclib…
Ascendia Pharmaceutical Solutions Launched to Meet Drug Development & Manufacturing Needs
Jim Huang, Ph.D., founder and CEO of Ascendia Pharmaceuticals, announces that the pharmaceutical contract development and manufacturing organization (CDMO) has re-branded to Ascendia Pharmaceutical Solutions.…
uniQure Announces Alignment With FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
uniQure N.V. recently announced the company reached agreement with the US FDA on key elements of an Accelerated Approval pathway for AMT-130. “We are very…
Zealand Pharma Announces First Participant Enrolled in Phase 2b Trial of Petrelintide in People With Overweight or Obesity
Zealand Pharma A/S recently announced the first participant has been enrolled in ZUPREME-1, a global Phase 2b trial in people with obesity or overweight with…
Eikonizo Therapeutics Announces Investment by Novo Nordisk; Advancing Lead Candidate Toward Clinical Development
Eikonizo Therapeutics recently announced it has secured an undisclosed equity investment from Novo Nordisk through its Science2Medicine iNNvest initiative. In addition to supporting the development…
Immutep Announces Initiation of Phase 3 Trial in First Line Non-Small Cell Lung Cancer
Immutep Limited recently announced the initiation of the pivotal TACTI-004 Phase 3 clinical trial for the treatment of first-line metastatic non-small cell lung cancer (1L…
Scienture Announces Issuance of New Patent Covering its First Product Losartan Potassium Oral Suspension Through 2041
SCIENTURE, LLC, a wholly owned subsidiary of SCIENTURE HOLDINGS, INC. recently announced that the U.S. Patent and Trademark Office (USPTO) has issued a new patent, No.…
IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001
IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced additional clinical data from ongoing analyses of results from the…
NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage
NurExone Biologic Inc., a biopharmaceutical company developing exosome-based regenerative therapies, has announced significant findings from an expanded preclinical study of the potential of its portfolio…
Bionical Emas Sells EMAS Pharma to Kester Capital Following Strategic Review
Bionical Emas is selling its Clinical Development division, EMAS Pharma, to Kester Capital and an incoming executive team. The decision to sell comes after a…
Medigene AG Announces KRAS G12V as First Target for TCR-Guided T Cell Engagers
Medigene AG recently announced the selection of Kirsten rat sarcoma viral oncogene homologue (KRAS) G12V, in the context of HLA*A11, as the initial target for the…
